✦ LIBER ✦

198 POSTER Multi-targeted inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuxiamb (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors

✍ Scribed by C. Lin; G. Preston; E. Calvo; K. Papadopoulos; A. Patnaik; J. Sarantopoulos; P. O'Rourke; C. Takimoto; A. Tolcher

Book ID: 118623826
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 60 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70203-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

552 Evaluation of the pharmacokinetic (P

552 Evaluation of the pharmacokinetic (PK) interactions between cetuximab and irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing advanced solid tumors. Results of a phase I study

✍ C. Delbaldo; J.Y. Pierga; V. Dieras; S. Faivre; M. Bonnay; J.C. Vedovato; M. Mue 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Phase I Pharmacokinetic and Pharmacodyna

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

✍ Paz-Ares, L. G.; Gomez-Roca, C.; Delord, J.-P.; Cervantes, A.; Markman, B.; Corr 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 192 KB

35 POSTER A Phase I trial of a combinati

35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 134 KB

93 POSTER Phase I study of daily oral AZ

93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; D. Jonker; M. Maclean; J. Wells; S. Mathews; J. Robertson; L. Seymour 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB